K T Douglas MA(Oxford) PhD(Kent at Canterbury)
Tel: +44 (0)161 275 2371
FAX: +44 (0)161 275 2396
Rational drug design/molecular graphics
Mechanistic enzymology and enzyme kinetics
Design of enzyme inhibitors as potential drug leads
Design of DNA and RNA ligands and their high-field NMR analysis
New chemical cleavage methods for nucleic acids
Synthesis of potential drug molecules
Disease interests: cancer, trypanosomiasis, leishmaniasis, malaria
Rational drug design
Protein structure and action
Enzyme mechanism and inhibition
Anticancer drug action
Director of Postgraduate Studies
Chairman, Teaching Standards Committee
Head, Drug Action and Design Group
B.A. (Hons.) Chemistry, Balliol College, Oxford University, 1966-1970
M.A., University of Oxford, 1973
Ph.D. Biological Chemistry, University of Kent at Canterbury, 1970-73
F.R.S.C, C.Chem; 1997
Fellow of the Royal Society of Chemistry
The Biochemical Society (London)
Society for Drug Research
British Association for Cancer Research
United Kingdom Association of Pharmaceutical Scientists
Brief Career Details
Professor of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences
Head of Department of Pharmacy (1991-1994)
Lecturer in Biological Chemistry, University of Essex, UK (1978-1987)
Associate Professor of Chemistry and Biochemistry, Duquesne University, Pittsburgh, USA
Assistant Professor of Chemistry and Biochemistry, Duquesne University, Pittsburgh, USA
Research Associate, Department of Chemistry, University of Chicago (1973-1975)
External Honours and Appointments
Professeur d'Echange, University de Paris-Sud, Orsay/C.N.R.S. (1978)
Honorary Professor, Nagasaki University (1983)
Matsumae Medal and International Fellow to Japan (1983)
Professeur Associé, University Paul-Sabatier, Toulouse (1991-92)
Awarded Sir Hans Sloane Medal for highest mark in 1966 A-level, GCE in Chemistry, Physics
and Biology (N.Ireland). Also awarded Royal Institute of Chemistry prize for highest
mark (boys) in GCE A-level, Chemistry, 1966.
Of approximately 160 refereed publications the following are typical:
"Improved efficiency and selectivity in peptide synthesis: use of triethylsilane as a
scavenger in deprotection of t-butyl esters and t-butoxycarbonyl-protected sites", by
R. Jaouhari, T.J. Benson and K.T. Douglas, Tetrahed. Lett., (1992) 33, 5441-5444.
"Sequence-dependent reactivity of linear DNA to chemical cleavage by Cu(II):thiol
including cysteine or glutathione", by D.C.A. John and K.T. Douglas, Biochem. J.,
"Site-directed mutagenesis of glutamic acid 172 to glutamine completely inactivated
O6-alkylguanine-DNA-alkyltransferase", by J.A. Rafferty, J. Tumelty, R.H.
Elder, M. Skorvaga,
G.P. Margison and K.T. Douglas, Biochem. Biophys. Res. Commun. (1994) 199, 285-291.
"Photoaffinity labelling of the active-site of the rat liver glutathione
S-transferases 3-3 and 1-1 and
human glutathione transferase A1-1", by R.J. Cooke, K.T. Douglas, J.H. McKie, M.D.
Coles, B. Ketterer, R. Bjørnstedt, B. Mannervik, Biochem. J. (1994) 302, 383-390.
"Molecular Design of DNA-directed Ligands with Specific Interactions: Solution NMR
of the Interaction of a meta-hydroxy analogue of Hoechst 33258 with d(CGCGAATTCGCG)2,
by J.A. Parkinson, S.E. Ebrahimi, J.H. McKie and K.T. Douglas, Biochemistry (1994) 33,
"Rational Drug Design in Parasitology", by K.T. Douglas, Parasitology Today
"A Homology Model of the three-dimensional structure of Human O6-alkylguanine
DNA-alkyltransferase based on the crystal structure of the C-terminal domain of the
Ada protein from Escherichia coli",
by J.E.A. Wibley, J.H. McKie, K.Embrey, D.S. Marks, K.T. Douglas, M.H. Moore,
P.C.E. Moody, Anti-Cancer Drug Design, 1995, 10, 75-95.
"Synthesis, DNA-binding, footprinting and in vitro antitumour activity of a
analogue of Hoechst 33258", by S. E. Sadat Ebrahimi, M. C. Bibby, K. R. Fox, and K.
Douglas, Anti-Cancer Drug Design, 1995, 10, 463-479.
"Site-Directed Mutagenesis of a Serine Residue in Cinnamyl Alcohol Dehydrogenase, a
NADPH-Dependent Dehydrogenase, Affects the Specificity for the Coenzyme", by V.
Lauvergeat, K. Kennedy, C. Feuillet, J. H. McKie, L.Gorrichon, M. Baltas, A. M. Boudet, J.
Grima-Pettenati and K. T. Douglas, Biochemistry,1995, 34, 12426-434.
"Predictability of Designing Specific Binding Interactions for DNA Minor Groove
NMR Spectroscopy and Molecular Modelling: A Copper (II)-Activated DNA
Cleaver based on Hoechst 33258", J. A. Parkinson, S. Sadat-Ibrahimi, A. Wilton, J. H.
McKie, J. Andrews and K. T. Douglas, Biochemistry, (1995) 34, 16240-44.
"A Homology Model of the Id-3 helix-loop-helix domain as a basis for
predictions", by J. E. A. Wibley, R. Deed, M. Jasiok, K. T. Douglas, and J. D.
Biophys. Acta, (1996)1294, 138-146
"A Unique Binding Site for Bis-benzimidazoles on transfer RNA" by
S.E.Ebrahimi, A.N.Wilton, K.T.Douglas, Chem.Commun.,(1997),385-386
"A Common Chemical Mechanism Used for DNA cleavage by Copper (II)Activated by
Thiols and Ascorbate is Distinct from that for Cu(II) :Hydrogen Peroxide Cleavage",
by D.C.A. John and K.T.Douglas, Transition Metal Chem.,(1996)21,460-463
"Structural Investigation of a Binary-Addressed Oligonucleotide System Juxtaposing
Pyrene and Perfluouoazide Units by means of High-Field NMR spectroscopy and Molecular
Modeling" by E.V.Bichenkova, D.S.Marks, S.G.Lokhov, M.I. Dobrikov, V.Vlassov and
K.T.Douglas, J Biomol. Struct.Dynamics(1997), 15, 307-320
"Phenothiazine Inhibitors of Trypanothione Reductase as Potential
Antritrypanosomal and Antileishmanial Drugs" by C.C. Chan, H.Yin, J.Garforth,
J.H.McKie, R.Jaohari, P.Speers, K.T.Douglas, P.J.Rock, V.Yardley, S.L.Croft and
A.H.Fairlamb, J.Med.Chem.,(1998)41, 148-156
"A Rational Drug Design Approach to Overcoming Drug Resistance: Application to
Pyrimethamine in Malaria" by J.H.McKie, K.T.Douglas, C.Chan, S.A.Roser, R.Yates,
M.Reid, J.E Hyde, M.JDascombe, Y.Yuthavong and W.Sirawaraporn, J.Med.Chem.,(1998) 41,